type 1 diabetes
Endocrinology · 2006–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| insulin degludec Treatment of type 1 diabetes mellitus in patients aged 1 year or older, as an alternative to insulin glargine 100 IU/mL and to replace insulin detemir… | Jul 2025 | Recommended with restriction | input received DANII Foundation · Diabetes Alliance · Australian Diabetes Society |
| insulin aspart Treatment of diabetes mellitus. Truvelog is a biosimilar to the reference brand NovoRapid, registered for the same indication. | Nov 2021 | Recommended | none received |
| insulin glargine Type 1 and Type 2 diabetes mellitus. Biosimilar brand of insulin glargine for patients requiring insulin therapy. | Jul 2018 | Recommended | none received |
| insulin glargine Treatment of type 1 diabetes mellitus in adults and children and type 2 diabetes mellitus in adults who require insulin for the control of hyperglycaemia. | Mar 2015 | Recommended | no section in document |
| insulin detemir Treatment of Type 1 diabetes patients requiring intensive insulin therapy with 3 or more injections of insulin per day with one of the insulins being a short… | Mar 2006 | Recommended with restriction | no section in document |
| insulin glargine Treatment of Type 1 diabetes mellitus in adults and children, and Type 2 diabetes mellitus in adults who require insulin for the control of hyperglycaemia. | Mar 2006 | Recommended | no section in document |
| insulin detemir Treatment of Type 1 diabetes requiring intensive insulin therapy with 3 or more injections of insulin per day, including one short-acting insulin. Also for… | Mar 2006 | Recommended with restriction | no section in document |
| insulin glargine Treatment of Type 1 diabetes mellitus in adults and children, and Type 2 diabetes mellitus in adults who require insulin for control of hyperglycaemia. | Mar 2006 | Recommended | no section in document |
Who spoke
DANII Foundation · Diabetes Alliance · Australian Diabetes Society
What the PBS pays
$298M in government benefit over 2024–25, across 1,258,610 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| insulin aspart | $142.1M |
| insulin glargine | $73.4M |
| insulin degludec | $72.8M |
| insulin detemir | $9.8M |
Appraised elsewhere
NICE, in England and Wales, has appraised 2 technologies for this condition, recommending 2 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| teplizumabTeplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes | TA1176 | recommended restricted | 2026-07 |
| hybrid closed loop systemsHybrid closed loop systems for managing blood glucose levels in type 1 diabetes | TA943 | recommended | 2023-12 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| insulinACTRAPID PENFILL human insulin (rys) 100IU/mL injection multidose cart | 1991 | 13 |
| insulin icodecAWIQLI insulin icodec 1050 U in 1.5 mL solution for injection pre-fill | 2024 | 6 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.